Literature DB >> 28665504

Prognostic value of nasal cytology and clinical factors in nasal polyps development in patients at risk: can the beginning predict the end?

Eugenio De Corso1, Daniela Lucidi1, Mariapina Battista1, Matteo Romanello1, Carla De Vita1, Silvia Baroni2, Chiara Autilio2, Jacopo Galli1, Gaetano Paludetti1.   

Abstract

BACKGROUND: We evaluated the prognostic value of nasal cytology and clinical factors in predicting nasal polyp (NP) development in patients with history of nonallergic chronic sinonasal inflammation.
METHODS: This was a retrospective case-control study of 295 patients followed at our institution for a mean of 85.70 ± 19.41 months. According to the inclusion criteria we enrolled 84 cases with persistent eosinophilic nonallergic sinonasal inflammation (group A) and 106 cases with neutrophilic inflammation (group B), both without evidence of NPs at the baseline. We considered as controls 105 patients affected by nonallergic noninfectious vasomotor rhinitis without evidence of inflammation at nasal cytology (group C). Patients were checked every 6 months for NPs. Temporal analyses was performed by Kaplan-Mayer curves and odds ratios were evaluated by logistic regression analyses.
RESULTS: The percentage of patients that developed NPs was higher in group A (29/84 [34.52%]) than in group B (17/106 [16.03%]) and group C (5/104 [4.7%]) (p < 0.05). Logistic regression analyses showed that eosinophilic patients had a higher risk of NP development over the years than neutrophilic patients compared to controls (odds ratio [OR], 10.55 vs 3.2). We also demonstrated that hypereosinophilia, asthma, and aspirin intolerance may increase the OR differently in eosinophilic patients.
CONCLUSION: Our data suggest that early identification of inflammatory patterns and associated clinical factors in patients affected by chronic nonallergic sinonasal inflammation have a prognostic value that can help to identify patients with different risks of NP development. Our data confirm that detection of nasal eosinophilic inflammation represents an early marker for identification of a more aggressive inflammatory phenotype.
© 2017 ARS-AAOA, LLC.

Entities:  

Keywords:  allergy; asthma; chronic rhinosinusitis with nasal polyps; eosinophil; nonallergic rhinitis

Mesh:

Substances:

Year:  2017        PMID: 28665504     DOI: 10.1002/alr.21979

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  11 in total

1.  Predictive significance of arachidonate 15-lipoxygenase for eosinophilic chronic rhinosinusitis with nasal polyps.

Authors:  Zhuoping Liang; Bing Yan; Chang Liu; Ruyu Tan; Chengshuo Wang; Luo Zhang
Journal:  Allergy Asthma Clin Immunol       Date:  2020-09-16       Impact factor: 3.406

2.  Middle meatus nasal cytology compared to inferior turbinate cytology in non allergic rhinitis.

Authors:  Corso Bocciolini; Emanuele Nappi; Gianmarco Giunta; Giovanni Paoletti; Luca Malvezzi; Giulia Monti; Alberto Macchi; Luca Amorosa; Enrico Heffler
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-08-31       Impact factor: 3.236

3.  Effectiveness of Dupilumab in the Treatment of Patients with Severe Uncontrolled CRSwNP: A "Real-Life" Observational Study in the First Year of Treatment.

Authors:  Eugenio De Corso; Stefano Settimi; Claudio Montuori; Marco Corbò; Giulio Cesare Passali; Davide Paolo Porru; Simone Lo Verde; Camilla Spanu; Daniele Penazzi; Giuseppe Alberto Di Bella; Eleonora Nucera; Matteo Bonini; Gaetano Paludetti; Jacopo Galli
Journal:  J Clin Med       Date:  2022-05-10       Impact factor: 4.964

Review 4.  Personalized Management of Patients with Chronic Rhinosinusitis with Nasal Polyps in Clinical Practice: A Multidisciplinary Consensus Statement.

Authors:  Eugenio De Corso; Maria Beatrice Bilò; Andrea Matucci; Veronica Seccia; Fulvio Braido; Matteo Gelardi; Enrico Heffler; Manuela Latorre; Luca Malvezzi; Girolamo Pelaia; Gianenrico Senna; Paolo Castelnuovo; Giorgio Walter Canonica
Journal:  J Pers Med       Date:  2022-05-23

5.  The SWI/SNF complex in eosinophilic and non eosinophilic chronic rhinosinusitis.

Authors:  Katarzyna Kowalik; Martyna Waniewska-Leczycka; Elzbieta Sarnowska; Natalia Rusetska; Marcin Ligaj; Alicja Chrzan; Mariola Popko
Journal:  Acta Otorhinolaryngol Ital       Date:  2021-04       Impact factor: 2.124

6.  Chronic rhinosinusitis with polyposis and serum vitamin D levels.

Authors:  F Bavi; R Movahed; M Salehi; S Hossaini; M Bakhshaee
Journal:  Acta Otorhinolaryngol Ital       Date:  2019-10       Impact factor: 2.124

7.  Exploring the role of nasal cytology in chronic rhinosinusitis.

Authors:  Stefania Gallo; Francesco Bandi; Andrea Preti; Carla Facco; Giorgia Ottini; Federica Di Candia; Francesco Mozzanica; Laura Saderi; Fausto Sessa; Marcella Reguzzoni; Giovanni Sotgiu; Paolo Castelnuovo
Journal:  Acta Otorhinolaryngol Ital       Date:  2020-10       Impact factor: 2.124

8.  Efficacy of Biologics on Refractory Eosinophilic Otitis Media Associated with Bronchial Asthma or Severe Uncontrolled CRSwNP.

Authors:  Eugenio De Corso; Claudio Montuori; Stefano Settimi; Dario Antonio Mele; Alessandro Cantiani; Marco Corbò; Elena Cantone; Gaetano Paludetti; Jacopo Galli
Journal:  J Clin Med       Date:  2022-02-10       Impact factor: 4.241

Review 9.  Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: a change management approach. Consensus of the Joint Committee of Italian Society of Otorhinolaryngology on biologics in rhinology.

Authors:  Eugenio De Corso; Gianluca Bellocchi; Michele De Benedetto; Nicola Lombardo; Alberto Macchi; Luca Malvezzi; Gaetano Motta; Fabio Pagella; Claudio Vicini; Desiderio Passali
Journal:  Acta Otorhinolaryngol Ital       Date:  2021-07-23       Impact factor: 2.618

10.  Clinical Evidence and Biomarkers Linking Allergy and Acute or Chronic Rhinosinusitis in Children: a Systematic Review.

Authors:  Eugenio De Corso; Daniela Lucidi; Elena Cantone; Giancarlo Ottaviano; Tiziana Di Cesare; Veronica Seccia; Gaetano Paludetti; Jacopo Galli
Journal:  Curr Allergy Asthma Rep       Date:  2020-09-05       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.